---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-041305"
form_type: "8-K"
ticker: "KZR"
cik: "0001645666"
company_name: "Kezar Life Sciences, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T17:52:42.056458+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Kezar Life Sciences Q2 net loss $24.3M; cash $236.6M; clinical trials advancing

## Summary
- Net loss of $24.3M ($0.34 per share) vs $16.2M ($0.25) in Q2 2022.
- Cash equivalents and marketable securities $236.6M at June 30, 2023, down from $276.6M at Dec 31, 2022.
- R&D expenses rose to $21.0M from $11.3M year-over-year, driven by zetomipzomib and KZR-261 programs.
- PALIZADE Phase 2b (lupus nephritis) and PORTOLA Phase 2a (autoimmune hepatitis) open for enrollment; KZR-261 dose escalation continues.

## SEC filing metadata
- accession: 0000950170-23-041305
- form_type: 8-K
- ticker: KZR
- cik: 0001645666
- company_name: Kezar Life Sciences, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645666/000095017023041305/0000950170-23-041305-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645666/000095017023041305/kzr-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-041305
- JSON: https://secwatch.observer/filing/0000950170-23-041305.json
- Plain text: https://secwatch.observer/filing/0000950170-23-041305.txt

## Key facts
- Earnings Releases
  Kezar Life Sciences, Inc. reported financial results for the second quarter ended June 30, 2023.
  - Period: the second quarter ended June 30, 2023
  - Result: reported results
  source text: On August 10, 2023, Kezar Life Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645666/000095017023041305/0000950170-23-041305-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.